Cocrystal Pharma Inc. (COCP) stock surged over 75% after the FDA granted Fast Track designation to its norovirus drug candidate CDI-988. The status enables faster development, closer FDA interaction, and potential priority review. The company sees the treatment as both preventive and therapeutic, boosting investor optimism.